Amphastar Pharmaceuticals, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2016 | $36.0M | $329.3M | $72.4M |
| FY2017 | $45.7M | $333.7M | $65.6M |
| FY2018 | $49.1M | $332.4M | $86.3M |
| FY2019 | $46.3M | $381.4M | $73.7M |
| FY2020 | $45.9M | $402.3M | $92.6M |
| FY2021 | $78.2M | $445.5M | $126.4M |
| FY2022 | $76.6M | $528.7M | $156.1M |
| FY2023 | $603.2M | $639.4M | $144.3M |
| FY2024 | $613.5M | $732.3M | $151.6M |
| FY2025 | $619.7M | $788.8M | $170.2M |